BLACK DIAMOND THERAPEUTICS I (BDTX) Fundamental Analysis & Valuation

NASDAQ:BDTX • US09203E1055

Current stock price

2.03 USD
-0.1 (-4.69%)
At close:
2.0391 USD
+0.01 (+0.45%)
After Hours:

This BDTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. BDTX Profitability Analysis

1.1 Basic Checks

  • BDTX had positive earnings in the past year.
  • In the past year BDTX had a positive cash flow from operations.
  • BDTX had negative earnings in 4 of the past 5 years.
  • BDTX had negative operating cash flow in 4 of the past 5 years.
BDTX Yearly Net Income VS EBIT VS OCF VS FCFBDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • BDTX's Return On Assets of 15.64% is amongst the best of the industry. BDTX outperforms 95.76% of its industry peers.
  • Looking at the Return On Equity, with a value of 19.93%, BDTX belongs to the top of the industry, outperforming 95.57% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 12.33%, BDTX belongs to the best of the industry, outperforming 94.80% of the companies in the same industry.
Industry RankSector Rank
ROA 15.64%
ROE 19.93%
ROIC 12.33%
ROA(3y)-31.06%
ROA(5y)-40.44%
ROE(3y)-44.78%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
BDTX Yearly ROA, ROE, ROICBDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • With an excellent Profit Margin value of 31.95%, BDTX belongs to the best of the industry, outperforming 95.38% of the companies in the same industry.
  • With an excellent Operating Margin value of 28.39%, BDTX belongs to the best of the industry, outperforming 95.95% of the companies in the same industry.
Industry RankSector Rank
OM 28.39%
PM (TTM) 31.95%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDTX Yearly Profit, Operating, Gross MarginsBDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BDTX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BDTX is creating some value.
  • Compared to 1 year ago, BDTX has more shares outstanding
  • The number of shares outstanding for BDTX has been increased compared to 5 years ago.
  • BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BDTX Yearly Shares OutstandingBDTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
BDTX Yearly Total Debt VS Total AssetsBDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -0.37, we must say that BDTX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BDTX (-0.37) is comparable to the rest of the industry.
  • BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -0.37
ROIC/WACC1.32
WACC9.37%
BDTX Yearly LT Debt VS Equity VS FCFBDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 8.42 indicates that BDTX has no problem at all paying its short term obligations.
  • BDTX has a Current ratio of 8.42. This is in the better half of the industry: BDTX outperforms 74.95% of its industry peers.
  • A Quick Ratio of 8.42 indicates that BDTX has no problem at all paying its short term obligations.
  • BDTX's Quick ratio of 8.42 is fine compared to the rest of the industry. BDTX outperforms 74.95% of its industry peers.
Industry RankSector Rank
Current Ratio 8.42
Quick Ratio 8.42
BDTX Yearly Current Assets VS Current LiabilitesBDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BDTX Growth Analysis

3.1 Past

  • BDTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 129.13%, which is quite impressive.
EPS 1Y (TTM)129.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BDTX will show a very negative growth in Earnings Per Share. The EPS will decrease by -16.19% on average per year.
  • Based on estimates for the next years, BDTX will show a quite strong growth in Revenue. The Revenue will grow by 12.17% on average per year.
EPS Next Y-273.68%
EPS Next 2Y-116.67%
EPS Next 3Y-60.63%
EPS Next 5Y-16.19%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y12.17%

3.3 Evolution

BDTX Yearly Revenue VS EstimatesBDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2029 2030 2031 2032 2033 200M 400M 600M
BDTX Yearly EPS VS EstimatesBDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

4

4. BDTX Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 5.49, the valuation of BDTX can be described as very cheap.
  • Compared to the rest of the industry, the Price/Earnings ratio of BDTX indicates a rather cheap valuation: BDTX is cheaper than 97.88% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 24.88. BDTX is valued rather cheaply when compared to this.
  • The Forward Price/Earnings Ratio is negative for BDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 5.49
Fwd PE N/A
BDTX Price Earnings VS Forward Price EarningsBDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, BDTX is valued cheaper than 99.42% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.91
EV/EBITDA -5.97
BDTX Per share dataBDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • BDTX's earnings are expected to decrease with -60.63% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-116.67%
EPS Next 3Y-60.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BDTX Dividend Analysis

5.1 Amount

  • BDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BDTX Fundamentals: All Metrics, Ratios and Statistics

BLACK DIAMOND THERAPEUTICS I

NASDAQ:BDTX (3/27/2026, 8:02:11 PM)

After market: 2.0391 +0.01 (+0.45%)

2.03

-0.1 (-4.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)05-11
Inst Owners77.87%
Inst Owner Change-23.42%
Ins Owners0.62%
Ins Owner Change0.26%
Market Cap115.65M
Revenue(TTM)70.00M
Net Income(TTM)22.37M
Analysts84
Price Target9.91 (388.18%)
Short Float %8.2%
Short Ratio5.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.41%
Min EPS beat(2)-42.12%
Max EPS beat(2)37.31%
EPS beat(4)3
Avg EPS beat(4)1110.25%
Min EPS beat(4)-42.12%
Max EPS beat(4)4421.34%
EPS beat(8)7
Avg EPS beat(8)563.79%
EPS beat(12)11
Avg EPS beat(12)380.08%
EPS beat(16)15
Avg EPS beat(16)287.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.46%
PT rev (3m)5.02%
EPS NQ rev (1m)-894.88%
EPS NQ rev (3m)-894.88%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 5.49
Fwd PE N/A
P/S 1.65
P/FCF 3.91
P/OCF 3.91
P/B 1.03
P/tB 1.03
EV/EBITDA -5.97
EPS(TTM)0.37
EY18.23%
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)0.52
FCFY25.61%
OCF(TTM)0.52
OCFY25.61%
SpS1.23
BVpS1.97
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.05
Profitability
Industry RankSector Rank
ROA 15.64%
ROE 19.93%
ROCE 15.61%
ROIC 12.33%
ROICexc N/A
ROICexgc N/A
OM 28.39%
PM (TTM) 31.95%
GM N/A
FCFM 42.31%
ROA(3y)-31.06%
ROA(5y)-40.44%
ROE(3y)-44.78%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 146.64%
Profit Quality 132.4%
Current Ratio 8.42
Quick Ratio 8.42
Altman-Z -0.37
F-Score9
WACC9.37%
ROIC/WACC1.32
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)129.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
EPS Next Y-273.68%
EPS Next 2Y-116.67%
EPS Next 3Y-60.63%
EPS Next 5Y-16.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y12.17%
EBIT growth 1Y125.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-437.77%
EBIT Next 3Y-84.88%
EBIT Next 5Y-19.23%
FCF growth 1Y147.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y147.53%
OCF growth 3YN/A
OCF growth 5YN/A

BLACK DIAMOND THERAPEUTICS I / BDTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BLACK DIAMOND THERAPEUTICS I?

ChartMill assigns a fundamental rating of 4 / 10 to BDTX.


What is the valuation status for BDTX stock?

ChartMill assigns a valuation rating of 4 / 10 to BLACK DIAMOND THERAPEUTICS I (BDTX). This can be considered as Fairly Valued.


How profitable is BLACK DIAMOND THERAPEUTICS I (BDTX) stock?

BLACK DIAMOND THERAPEUTICS I (BDTX) has a profitability rating of 4 / 10.


Can you provide the financial health for BDTX stock?

The financial health rating of BLACK DIAMOND THERAPEUTICS I (BDTX) is 7 / 10.